Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies
The clinical development program of the direct-acting antiviral (DAA) combination therapy of paritaprevir (coadministered with ritonavir) and ombitasvir, with and without dasabuvir (3-DAA [3D] and 2-DAA [2D] regimens, respectively) used in the treatment of chronic hepatitis C infection has generated a robust dataset across various dosing regimens and patient populations.
The current analysis aimed to characterize the population pharmacokinetics in patients without cirrhosis (‘non-cirrhotic’) and with compensated cirrhosis (‘cirrhotic’), while accounting for differences across hepatitis C virus (HCV) genotypes (GT) 1, 2, and 4, multiple regimens (3D regimen ± ribavirin for GT1 in global studies, 2D regimen for subgenotype 1b in Japan, 2D regimen + ribavirin for GT2 in Japan, and 2D regimen + ribavirin for GT4), and ethnicities.
Pharmacokinetic data from nine clinical studies (~ 1850 patients) were used to model the population pharmacokinetics of each component of the DAA regimens. Model development was performed in stages, starting with an initial base model. Covariate–parameter relationships were then assessed using forward inclusion/backward elimination procedures. Model development was guided by goodness-of-fit plots, likelihood ratio tests, plausibility of parameter estimates, and knowledge of DAA, ritonavir, and ribavirin pharmacokinetics. Paritaprevir, ombitasvir, and ritonavir pharmacokinetics were described by a one-compartment model, while dasabuvir and ribavirin pharmacokinetics were characterized by a two-compartment model.
The analysis showed generally overlapping exposures between compensated cirrhotic and non-cirrhotic patients or between subgroups of the identified significant covariates. The largest differences were the approximately 30–60% higher dasabuvir and paritaprevir exposures in compensated cirrhotic patients.
These differences did not warrant dose adjustments for the DAAs when used in HCV-infected patients with compensated cirrhosis.
The authors acknowledge Eva Dölger and Doerthe Eckert of AbbVie for their assistance with the manuscript figures and Amy Rohrlack of AbbVie for her medical writing support.
Compliance with Ethical Standards
Financial support was provided by AbbVie. All authors participated in the interpretation of data, review, and approval of the manuscript.
Conflict of interest
Sathej Gopalakrishnan, Sven Mensing, Rajeev M. Menon, and Jiuhong Zha are employees of AbbVie and may hold AbbVie stock or stock options. Medical writing support was provided by Amy Rohrlack, an AbbVie employee.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the studies that were included in this analysis.
- 11.Asselah T, Hézode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1(1):25–35.CrossRefPubMedGoogle Scholar
- 14.Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir [poster]. In: AASLD/EASL special conference on hepatitis C; 3–5 Oct 2014; New York.Google Scholar
- 18.Center for Drug Evaluation and Research (CDER). Summary review for regulatory action: Viekira Pak™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets). Rockville: CDER; 2014.Google Scholar
- 20.Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [US package insert]. North Chicago: AbbVie Inc.; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206619s013s015lbl.pdf. Accessed 21 Feb 2018.
- 21.Technivie (ombitasvir, paritaprevir, and ritonavir tablets) [US package insert]. North Chicago: AbbVie Inc.; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207931s011lbl.pdf. Accessed 21 Feb 2018.
- 24.Olysio™ (simeprevir) [US package insert]. Titusville: Janssen Therapeutics; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205123s014lbl.pdf. Accessed 21 Feb 2018.
- 25.Crestor (rosuvastatin calcium) [US package insert]. Wilmington: AstraZeneca Pharmaceuticals LP; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021366s037lbl.pdf. Accessed 21 Feb 2018.